Reduced folate carrier and methylenetetrahydrofolate reductase gene polymorphisms: Associations with clinical outcome in childhood acute lymphoblastic leukemia

Leukemia

Volumn 23, Issue 7, 2009, Pages 1348-1351

  Ashton, L J ^a   Gifford, A J ^a   Kwan, E ^a   Lingwood, A ^a   Lau, D T T ^a   Marshall, G M ^a,b   Haber, M ^a   Norris, M D ^a  

^a CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^b SYDNEY CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; ALANINE; ARGININE; CYTOSINE; GENOMIC DNA; GLUTAMIC ACID; HISTIDINE; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); REDUCED FOLATE CARRIER; THYMINE; VALINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMINO ACID SUBSTITUTION; BINDING AFFINITY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CHILDHOOD LEUKEMIA; DNA ISOLATION; DOWN REGULATION; DRUG MEGADOSE; DRUG PROTEIN BINDING; ENZYME ACTIVITY; EVENT FREE SURVIVAL; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LETTER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION;

EID: 67650927350     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.67     Document Type: Letter

References (9)

1. Kager L, Cheok M, Yang W, Zaza G, Cheng Q, Panetta JC et al. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest 2005; 115: 110-116.
2. Laverdiere C, Chiasson S, Costea I, Moghrabi A, Krajinovic M. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate levels and outcome of childhood acute lymphoblastic leukemia. Blood 2002; 100: 3832-3834.
3. Krajinovic M, Lemieux-Blanchard E, Chiasson S, Primeau M, Costea I, Moghrabi A. Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenomics J 2004; 4: 66-72.
4. Rocha JC, Cheng C, Liu W, Kishi S, Das S, Cook EH et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 2005; 105: 4752-4758.
5. Schwahn B, Rozen R. Polymorphisms in the methylenetetrahydrofolate reductase gene. Clinical consequences. Am J Pharmacogenomics 2001; 1: 189-201.
6. Chango A, Emery-Fillon N, Potier de Courcy G, Lambert D, Pfister M, Rosenblatt DS et al. A polymorphism (80G→A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab 2000; 70: 310-315.
7. 27 carriers. Clin Cancer Res 2001; 7: 3416-3422.
8. Gast A, Bermejo JL, Flohr T, Stanulla M, Burwinkel B, Schrappe M et al. Folate metabolic gene polymorphisms and childhood acute lymphoblastic leukemia: A case-control study. Leukemia 2007; 21 320-325.
9. Dervieux T, Furst D, Lein DO, Capps R, Smith K, Walsh M et al. Polyglutamylation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 2004; 50: 2766-2774.